|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Corixa Corporation (CRXA) And Lorantis Announce Joint Collaboration To Develop Therapeutic Hepatitis B Vaccine
10/19/2005 5:12:54 PM
SEATTLE and CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--March 3, 2005--Corixa Corporation (Nasdaq:CRXA), a developer of immunotherapeutics, and Lorantis, a Cambridge, U.K.-based immunotherapy company, today announced a joint collaboration in which the companies will continue the development of a therapeutic hepatitis B vaccine, containing Corixa's RC-529(TM) adjuvant and Lorantis' CV-1831, a hepatitis B core antigen that was previously owned by Apovia, Inc.
This collaboration builds on the initial research and development conducted by Corixa and Apovia for the development of a therapeutic vaccine for the treatment of hepatitis B. Lorantis has acquired all of Apovia's interest in the hepatitis B vaccine technology and under the terms of the new agreement, Lorantis will assume many of Apovia's development responsibilities. The collaboration is managed by a joint management team where Corixa will take the lead for the regulatory applications and management of all clinical trials. Lorantis will lead the completion of preclinical studies and supply the hepatitis B core antigen. The companies will share equally in all costs and potential revenues associated with the development of the vaccine. Following proof-of-principle clinical trials, the companies intend to partner the vaccine to a late-stage development and commercialization organization.
|
|
|
|
|
|
|
|
|
|
|